---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028999"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:14:09.614556+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026

## Summary
- Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
- Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.
- GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.
- Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site.

## SEC filing metadata
- accession: 0001493152-25-028999
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028999
- JSON: https://secwatch.observer/filing/0001493152-25-028999.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028999.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Collaborative Research Agreement with The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: The University of Texas M.D. Anderson Cancer Center
  - Effective: 2025-12-17
  source text: On December 17, the Company entered into a Collaborative Research Agreement with the Anderson Cancer Center (the “Research Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amendment No.2 with GlaxoSmithKline LLC and The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: GlaxoSmithKline LLC and The University of Texas M.D. Anderson Cancer Center
  - Effective: 2025-12-17
  source text: On December 17, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into Amendment No.2 (“Amendment No.2”) to the GSK & LIXTE Supported Collaborative Study (the “Collaborative Study”) by and between the Company, GlaxoSmithKline LLC (“GSK”) and the University of Texas M.D. Anderson Cancer Center
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.